CONCORD : survie de patients atteints de cancer dans le monde


CONCORD Logo final

The CONCORD-2 study, published in The Lancet (2015), extended coverage to 25.7 million adults (15-99 years) diagnosed during the 15 years 1995-2009 with a cancer of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary or prostate, or leukaemia, and 75,000 children (0-14 years) with acute lymphoblastic leukaemia. Individual data on all these patients were submitted by 279 population-based cancer registries in 67 countries – 40 with national coverage of their population. Patients were followed up to 31 December 2009.

The 10 cancers examined in CONCORD-2 represent two-thirds (63%) of the overall cancer burden in both low- and middle- income, and high-income countries. The 67 participating countries are home to two-thirds of the world’s population.

- See more at: http://csg.lshtm.ac.uk/research/themes/concord-programme/#sthash.1vmNXh2n.dpuf

 

 

Le programme CONCORD piloté par le Cancer Survival Group de la London School of Hygiene & Tropical Medicine vise à étudier la survie des patients atteints de cancer à l'échelle mondiale.

Site Internet du Programme CONCORD.

 

 

Le deuxième volet de l'étude (CONCORD-2) comportait des données sur plus de 25,7 millions de personnes atteintes de cancers dans 67 pays. Les résultats de cette étude publiée dans le Lancet ont montré d'importantes disparités selon les pays :

Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X-S, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015 Mar 14;385(9972):977–1010.

 

 

Le registre des cancers du Bas-Rhin participe au programme CONCORD-2 et a contribué à l'analyse de la survie des patients atteints d'un cancer du poumon dans le monde.

Des résultats ont été présenté lors de la réunion des registres de langue latine (GRELL) de 2016 à Albi : Jégu J, Coleman MP, Bonaventure A, Allemani C, on behalf of the CONCORD Working Group. Conditional survival of patients diagnosed with lung cancer worldwide: a CONCORD-2 study. 40th Meeting of the Group for Epidemiology and Registration of Cancer of Latin Language Countries (GRELL); 2016 May 4; Albi, France.